## Yoshihisa Yamano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1209849/publications.pdf

Version: 2024-02-01

63 papers

2,352 citations

236925 25 h-index 214800 47 g-index

66 all docs 66
docs citations

66 times ranked 1556 citing authors

#	Article	IF	Citations
1	Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1–associated myelopathy (HAM/TSP). Blood, 2002, 99, 88-94.	1.4	252
2	$\mbox{HTLV-1-associated myelopathy/tropical spastic paraparesis.}$ Nature Reviews Disease Primers, 2015, 1, 15012.	30.5	175
3	Clinical Pathophysiology of Human T-Lymphotropic Virus-Type 1-Associated Myelopathy/Tropical Spastic Paraparesis. Frontiers in Microbiology, 2012, 3, 389.	3.5	157
4	Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-l–associated neuroimmunological disease. Journal of Clinical Investigation, 2005, 115, 1361-1368.	8.2	135
5	Increased HTLVâ€I proviral load and preferential expansion of HTLVâ€I taxâ€specific CD8 <sup>+</sup> T cells in cerebrospinal fluid from patients with HAM/TSP. Annals of Neurology, 2001, 50, 807-812.	5.3	127
6	Abnormally High Levels of Virus-Infected IFN-γ+CCR4+CD4+CD25+ T Cells in a Retrovirus-Associated Neuroinflammatory Disorder. PLoS ONE, 2009, 4, e6517.	2.5	104
7	HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. Journal of Clinical Investigation, 2014, 124, 3431-3442.	8.2	100
8	Increased Expression of Human T Lymphocyte Virus Type I (HTLV-I) Tax11-19 Peptide–Human Histocompatibility Leukocyte Antigen A*201 Complexes on CD4+ CD25+T Cells Detected by Peptide-specific, Major Histocompatibility Complex–restricted Antibodies in Patients with HTLV-l–associated Neurologic Disease. Journal of Experimental Medicine, 2004, 199, 1367-1377.	8.5	97
9	CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. PLoS Neglected Tropical Diseases, 2013, 7, e2479.	3.0	91
10	Usefulness of Proviral Load Measurement for Monitoring of Disease Activity in Individual Patients with Human T-Lymphotropic Virus Type I-Associated Myelopathy/Tropical Spastic Paraparesis. Journal of NeuroVirology, 2003, 9, 29-35.	2.1	85
11	Mogamulizumab (Anti-CCR4) in HTLV-1–Associated Myelopathy. New England Journal of Medicine, 2018, 378, 529-538.	27.0	79
12	Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain, 2013, 136, 2876-2887.	7.6	75
13	Neuroimmunity of HTLV-I Infection. Journal of NeuroImmune Pharmacology, 2010, 5, 310-325.	4.1	60
14	Human T-Lymphotropic Virus Type 1 (HTLV-1) and Regulatory T Cells in HTLV-1-Associated Neuroinflammatory Disease. Viruses, 2011, 3, 1532-1548.	3.3	51
15	Fucoidan Therapy Decreases the Proviral Load in Patients with Human T-Lymphotropic Virus Type-1-Associated Neurological Disease. Antiviral Therapy, 2011, 16, 89-98.	1.0	49
16	Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Frontiers in Microbiology, 2018, 9, 1651.	3.5	48
17	The Nature of the HTLV-1 Provirus in Naturally Infected Individuals Analyzed by the Viral DNA-Capture-Seq Approach. Cell Reports, 2019, 29, 724-735.e4.	6.4	46
18	Management of HAM/TSP. Neurology: Clinical Practice, 2021, 11, 49-56.	1.6	45

#	Article	IF	Citations
19	HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP. Journal of Neuroimmunology, 2017, 304, 51-55.	2.3	42
20	Mogamulizumab, an Anti-CCR4 Antibody, Targets Human T-Lymphotropic Virus Type 1–infected CD8 <sup>+</sup> and CD4 <sup>+</sup> T Cells to Treat Associated Myelopathy. Journal of Infectious Diseases, 2015, 211, 238-248.	4.0	37
21	IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathogens, 2017, 13, e1006597.	4.7	36
22	Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet Journal of Rare Diseases, 2016, 11, 69.	2.7	33
23	Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis. Modern Rheumatology, 2014, 24, 129-136.	1.8	32
24	Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation. New England Journal of Medicine, 2019, 380, 296-298.	27.0	32
25	Functional impairment of Tax-specific but not cytomegalovirus-specific CD8+ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers. Retrovirology, 2011, 8, 100.	2.0	31
26	Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study. Neurotherapeutics, 2017, 14, 1084-1094.	4.4	29
27	Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1–associated myelopathy/tropical spastic paraparesis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11685-11691.	7.1	28
28	An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers., 2021, 218, 107669.		26
29	Preapoptotic protease calpain-2 is frequently suppressed in adult T-cell leukemia. Blood, 2013, 121, 4340-4347.	1.4	21
30	Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet Journal of Rare Diseases, 2019, 14, 227.	2.7	21
31	The Relationship between Walking Speed and Step Length in Older Aged Patients. Diseases (Basel,) Tj ETQq1 1 (	).784314 2.5	rgBT/Overlo
32	Standardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study. Journal of Clinical Microbiology, 2015, 53, 3485-3491.	3.9	20
33	Impaired Taxâ€specific Tâ€cell responses with insufficient control of HTLVâ€1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer Science, 2009, 100, 481-489.	3.9	19
34	Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Frontiers in Microbiology, 2019, 10, 2110.	<b>3.</b> 5	17
35	The clinical impact of human T-lymphotrophic virus type 1 (HTLV-1) infection on the development of adult T-cell leukemia-lymphoma (ATL) or HTLV-1–associated myelopathy (HAM) / atypical HAM after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and renal transplantation. Journal of Clinical and Experimental Hematopathology: ICEH, 2018, 58, 107-121.	0.8	15
36	Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses, 2022, 14, 136.	3.3	15

#	Article	IF	CITATIONS
37	RAISING is a high-performance method for identifying random transgene integration sites. Communications Biology, 2022, 5, .	4.4	12
38	Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 321-323.	1.9	11
39	Genome wide association study of HTLV-1–associated myelopathy/tropical spastic paraparesis in the Japanese population. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
40	Development of reference material with assigned value for human Tâ $\in$ cell leukemia virus type 1 quantitative PCR in Japan. Microbiology and Immunology, 2018, 62, 673-676.	1.4	8
41	Advantage of higher-avidity CTL specific for Tax against human T-lymphotropic virus-1 infected cells and tumors. Cellular Immunology, 2011, 272, 11-17.	3.0	7
42	Preprocedural Carotid Plaque Echolucency as a Predictor of In-Stent Intimal Restenosis after Carotid Artery Stenting. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105339.	1.6	7
43	Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: a feasibility study. Pilot and Feasibility Studies, 2015, 1, 35.	1.2	5
44	Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet Journal of Rare Diseases, 2020, 15, 175.	2.7	4
45	Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy. International Journal of Hematology, 2021, 113, 765-769.	1.6	4
46	Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan. Orphanet Journal of Rare Diseases, 2021, 16, 355.	2.7	4
47	A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma. Medicine (United States), 2021, 100, e27450.	1.0	4
48	The Risk Factors for Death within 6 Months After Ischemic Stroke in Patients with Cancer. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105365.	1.6	3
49	Human T Lymphotropic Virus 1-Associated Myelopathy: Overview of Human T Cell Lymphotropic Virus-1/2 Tests and Potential Biomarkers. AIDS Research and Human Retroviruses, 2022, 38, 924-932.	1.1	3
50	The contribution of Asian researchers to the field of rheumatology. Nature Reviews Rheumatology, 2010, 6, 106-111.	8.0	2
51	Carotid ultrasound using superb microvascular imaging to identify patients developing in-stent restenosis after CAS. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106627.	1.6	2
52	Patient satisfaction survey for HAM-net registrants. Retrovirology, 2015, 12, .	2.0	1
53	Breath analysis for relapsing polychondritis assessed by ion mobility spectrometry. International Journal for Ion Mobility Spectrometry, 2015, 18, 177-183.	1.4	1
54	Human retrovirus promotes the plasticity of regulatory T cells into T helper type 1-like cells through the T-bet transcriptional activation in neuroinflammatory disease. Arthritis Research and Therapy, 2012, 14, .	3.5	0

#	Article	IF	CITATIONS
55	How does human Tâ€lymphotropic virus type 1 cause central nervous system disease? The importance of crossâ€talk between infected T cells and astrocytes. Clinical and Experimental Neuroimmunology, 2015, 6, 395-401.	1.0	O
56	Neuroimmunomodulation of Human T-Lymphotrophic Virus Type I/II Infection. , 2017, , 421-436.		O
57	VI. Diagnosis and Treatment of HTLV-1 Associated Myelopathy (HAM). The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1404-1409.	0.0	O
58	Targeting human Tâ€lymphotropic virus type 1â€infected cells with an antiâ€Câ€C chemokine receptor 4 antibody in Tâ€lymphotropic virus type 1â€associated myelopathy. Clinical and Experimental Neuroimmunology, 2018, 9, 153-154.	1.0	0
59	Soleal vein dilatation in the early phase of hospitalization is associated with subsequent development of deep vein thrombosis in patients with acute stroke. Journal of Medical Ultrasonics (2001), 2021, 48, 97-104.	1.3	0
60	HTLV-1 Infected CD4+CD25+CCR4+ T-Cells Disregulate Balance of Inflammation and Tolerance in HTLV-1 Associated Neuroinflammatory Disease., 2011,, 189-198.		0
61	Factors affecting post-ischemic stroke mortality in cancer patients. Nosotchu, 2021, , .	0.1	O
62	Forefront studies on human T ell leukemia virus typeÂ1â€associated myelopathy/tropical spastic paraparesis. Clinical and Experimental Neuroimmunology, 0, , .	1.0	0
63	Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy. Frontiers in Medicine, 2022, 9, 879379.	2.6	o